← Eichor
Condition: Pd 1 Antibody Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Pd 1 Antibody

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Phase 2 · 33 location(s) · SCRI Development Innovations, LLC · NCT06773910The Immune Assessment of PD-1 Antibody Therapy in Tumor
Phase N/A · 1 location(s) · Quanli Gao · NCT06693440A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Benefi
Phase 1/Phase 2 · 68 location(s) · BioNTech SE · NCT07111520A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Phase 2 · 83 location(s) · AstraZeneca · NCT07098338A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chem
Phase 2 · 24 location(s) · BioNTech SE · NCT07255404A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advance
Phase 3 · 312 location(s) · AstraZeneca · NCT06692738A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigati
Phase 1/Phase 2 · 14 location(s) · BioNTech SE · NCT07079631A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
Phase 1/Phase 2 · 1 location(s) · Akeso · NCT06642792Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
Phase 2 · 41 location(s) · UNICANCER · NCT06529718Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for L
Phase 2/Phase 3 · 261 location(s) · BioNTech SE · NCT06712316Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
Phase 1/Phase 2 · 1 location(s) · University of Virginia · NCT03161223A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327
Phase 1/Phase 2 · 88 location(s) · BioNTech SE · NCT06892548A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients
Phase 1 · 16 location(s) · OncoNano Medicine, Inc. · NCT06022029Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated S
Phase 3 · 221 location(s) · BioNTech SE · NCT06712355N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors
Phase 1/Phase 2 · 6 location(s) · Hefei Xinzhu Biological Technology Co., Ltd. · NCT07639450Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung
Phase 2 · 30 location(s) · BioNTech SE · NCT06841055Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Phase 3 · 317 location(s) · AstraZeneca · NCT07044336A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recu
Phase 2/Phase 3 · 295 location(s) · Bristol-Myers Squibb · NCT06926868177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
EARLY_Phase 1 · 5 location(s) · Radiopharm Theranostics, Ltd · NCT06305962Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Loc
Phase 1/Phase 2 · 18 location(s) · Aulos Bioscience, Inc. · NCT05267626ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Phase 3 · 155 location(s) · BioNTech SE · NCT07173751A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durval
Phase 1 · 19 location(s) · AstraZeneca · NCT07391670A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
Phase 1/Phase 2 · 1 location(s) · Wuhan YZY Biopharma Co., Ltd. · NCT05543330A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients Wit
Phase 2 · 6 location(s) · BioNTech SE · NCT07297212This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and
Phase 1 · 8 location(s) · ABL Bio, Inc. · NCT04762641A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-
Phase 3 · 1 location(s) · Shanghai Junshi Bioscience Co., Ltd. · NCT06170489Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
Phase 1/Phase 2 · 11 location(s) · OSE Immunotherapeutics · NCT05751798FS222 First in Human Study in Patients With Advanced Malignancies
Phase 1 · 21 location(s) · invoX Pharma Limited · NCT04740424A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in
Phase 3 · 267 location(s) · Merck Sharp & Dohme LLC · NCT06841354A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With An
Phase 1/Phase 2 · 68 location(s) · BioNTech SE · NCT06827236
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.